Recent results demonstrated that pyrotinib, an irreversible pan‐ERBB2 inhibitor, increased DNA damage and enhanced the radiosensitivity of HER2‐overexpressing gastric and breast cancer cells in vitro and in vivo. This evidence concerns the gene ERBB2 and breast carcinoma.